Cancer Immunology and Oncolytic Virology: Technologies and Global Markets

  • ID: 4231947
  • Report
  • Region: Global
  • 164 Pages
  • BCC Research
1 of 6
The Global Cancer Immunotherapy Market Should Reach $96.5 Billion by 2021 from $73.0 Billion in 2016 at a CAGR of 5.7%

FEATURED COMPANIES

  • Abbvie Inc.
  • Avax Technologies
  • Daiichi Sankyo Co.
  • Immunomedics Inc.
  • Merck Serono
  • Sanofi SA
  • MORE

Report Includes

  • An overview of the global markets for cancer immunotherapies and oncolytic virology.
  • Analyses of global market trends, with data from 2015, 2016, and projections of compound annual growth rates (CAGRs) through 2021.
  • Analyses of factors influencing market demand, such as clinical guidelines, demographic changes, and market saturation.
  • Information covering the latest trends, market structure, market size, key drug segments, and trends in technology.
  • Coverage of colony stimulating factors (CSFs), interferon alfa and gamma products, interleukin products and therapeutic monoclonal antibodies, including antibody conjugates, cancer vaccines, and other cancer treatment immunology products.
  • Technological discussions, including the current state, newly issued patents, and pending applications.
  • Profiles of leading companies in the industry.

Report Scope

The scope of this report covers current cancer immunotherapy markets for most common cancers. The market segments included in this report are therapeutic monoclonal antibodies (with special focus on checkpoint inhibitors), synthetic interleukins, interferons, and colony-stimulating factors; small kinase inhibitors of cancer-related targets; protective and therapeutic cancer vaccines; and adoptive cell therapies. This report also covers treatments that are in development for late-stage and early-stage oncolytic viruses. Detailed epidemiological information, discussion of incidence and mortality trends, overview of regulatory landscapes, and analysis of market shares for leading products and companies are also included in this report.

Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Abbvie Inc.
  • Avax Technologies
  • Daiichi Sankyo Co.
  • Immunomedics Inc.
  • Merck Serono
  • Sanofi SA
  • MORE

1: Introduction

  • Goals and Objectives
  • Reasons for Doing This Study
  • Intended Audience
  • Scope of The Study
  • Information Sources for the Technology Assessment
  • Forecasting Methodology
  • Geographic Breakdown

2: Summary and Highlights

  • Table 1 : Summary Table: Global Market for Cancer Immunotherapy, by Region, Through 2021
  • Figure 1 : Summary Figure: Global Market for Cancer Immunotherapy, by Region, 2015-2021

3: Overview

  • Past and Present of Cancer Immunology
  • What is Cancer?
  • Treating Cancer
  • Challenges in Treating Cancer
  • Cancer and the Immune System
  • Immunotherapy
  • Towards Combination Immunotherapy
  • Focusing on Cell-mediated Adaptive Immunity
  • Fine Tuning Versus Boosting Cancer Immunity
  • Early Versus Advanced Stage Cancer Immunotherapy
  • Personalized Treatment Paradigm
  • Clinically Significant Types of Cancers
  • Future of Checkpoint Inhibitors, Cancer Vaccines, and Oncolytic Virology

4: Overview of Cancer Immunotherapy

  • Immune System and Immunotherapy
  • Therapeutic Monoclonal Antibodies
  • Checkpoint Inhibitors
  • Biological Response Modifiers
  • Vaccines
  • Other
  • Expanded Information on Selected Product Candidates and Recent Regulatory Applications

5: Oncolytic Virology

  • Oncolytic Virotherapy

6: Major Markets

  • Markets for Immunotherapy Products
  • Markets for Oncolytic Virology Products

7: Company Profiles

  • Abbvie Inc.
  • Adaptimmune
  • Aduro Biotech
  • Advantagene
  • Advaxis Immunotherapies
  • Amgen
  • Argos Therapeutics
  • Ariad Pharmaceuticals
  • Arog Pharmaceuticals
  • Aserta Pharmaceuticals
  • Astellas
  • Astrazeneca
  • Avax Technologies
  • Bavarian Nordic
  • Bayer Healthcare
  • Biovex
  • Boehringer Ingelheim
  • Boston Biomedical
  • Bristol-Myers Squibb
  • Cell Medica
  • Celldex Therapeutics
  • Celgene Corp.
  • Chugai
  • Cold Genesys
  • Daiichi Sankyo Co.
  • Dendreon
  • Dnatrix
  • Eisai
  • Eli Lilly
  • F Hoffmann La Roche AG
  • Genelux
  • Gilead Sciences Inc.
  • Glaxosmithkline Plc
  • Hanmi Pharmaceutical
  • Heat Biologics
  • Immune Design
  • Immunocellular Therapeutics Ltd.
  • Immunomedics Inc.
  • Immunovaccine Inc.
  • Immunovative Therapies
  • Incyte Ciorp.
  • Inovio Pharmaceuticals Inc.
  • Janssen Pharmaceuticals
  • Kadmon Pharmaceuticals Corp.
  • Kite Pharmaceuticals Inc.
  • Kyowa Hakko Kirin Co. Ltd.
  • Ligand Pharmaceuticals Inc.
  • Lion Biotechnologies
  • Lokon Pharmaceuticals AB
  • Medimmune
  • Merck & Co.
  • Merck Kgaa
  • Merck Serono
  • Medigene AG
  • Mirati Therapeutics
  • Multivir Inc.
  • Newlink Genetics
  • Northwest Biotherapeutics
  • Novartis Pharma Services AG
  • Oncolys Biopharma Inc.
  • Oncolytics Biotech Inc.
  • Oncomed Pharmaceuticals Inc.
  • Oncos Therapeutics Ltd.
  • Ono Pharmaceutical Co.
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Plexxikon Inc.
  • Portola Pharmaceuticals Inc.
  • Provectus Biopharmacueticals Inc.
  • Psioxus Therapeutics Ltd.
  • Sanofi SA
  • Seattle Genetics
  • Shanghai Sunway Biotech Co. Ltd.
  • Shenzhen Sibiono Gentech
  • Sillajen Biotherapeutics Inc.
  • Spectrum Pharmaceuticals
  • Takara Bio Inc.
  • Takeda Co. Ltd.
  • Tapimmune Inc.
  • Targovax
  • Teva Pharmaceutical Industries Ltd.
  • TG Therapeutics Inc.
  • Tracon Pharmaceuticals Inc.
  • Transgene
  • VCN Biosciences
  • Ventirx
  • Verastem Inc.
  • Viralytics Ltd.
  • Virttu Biologics Ltd
  • Vyriad
  • Western Oncolytics Ltd.

List of Tables

Table 1 : Summary Table: Global Market for Cancer Immunotherapy, by Region, Through 2021
Table 2 : Stages of Lung Cancer
Table 3 : Approved Monoclonal Antibodies
Table 4 : Approved Antibody Drug Conjugates
Table 5 : Selected Therapeutic Monoclonal Antibodies in Clinical Trial
Table 6 : Approved Checkpoint Inhibitors
Table 7 : Selected Checkpoint Inhibitors in Clinical Trials
Table 8 : Selected Approved Interferon Alpha Analogues
Table 9 : Selected Approved Colony-Stimulating Factors
Table 10 : Selected Clinical-Stage Cancer Vaccines in Development
Table 11 : Selected Clinical-Stage Small-Molecule Immunotherapies in Development
Table 12 : Global Market for Immunotherapy Products, by Region, Through 2021
Table 13 : Global Market for Immunotherapy Products, by Treatment Category, Through 2021
Table 14 : U.S. Market for Immunotherapy Products, by Treatment Category, Through 2021
Table 15 : European Market for Immunotherapy Products, by Treatment Category, Through 2021
Table 16 : Japanese Market for Immunotherapy Products, by Treatment Category, Through 2021
Table 17 : Rest of the World Market for Immunotherapy Products, by Treatment Category, Through 2021
Table 18 : Global Market for Immunotherapy Products, by Cancer Indication, Through 2021
Table 19 : Global Market for Immunotherapy Products for Lung Cancer Treatment, by Region, Through 2021
Table 20 : Global Market for Immunotherapy Products for Breast Cancer Treatment, by Region, Through 2021
Table 21 : Global Market for Immunotherapy Products for Leukemia Treatment, by Region, Through 2021
Table 22 : Global Market for Immunotherapy for Myeloma Treatment, by Region, Through 2021
Table 23 : Global Market for Immunotherapy Products for Colorectal Cancer Treatment, by Region, Through 2021
Table 24 : Global Market for Immunotherapy Products for Lymphoma Treatment, by Region, Through 2021
Table 25 : Global Market for Immunotherapy Products for Melanoma Treatment, by Region, Through 2021
Table 26 : Global Market for Immunotherapy Products for Kidney Cancer Treatment, by Region, Through 2021
Table 27 : Global Market for Immunotherapy Products for Bladder Cancer Treatment, by Region, Through 2021
Table 28 : Global Market for Immunotherapy Products for Head and Neck Cancer Treatment, by Region, Through 2021
Table 29 : Global Market for Immunotherapy Products for Stomach Cancer Treatment, by Region, Through 2021
Table 30 : Global Market for Immunotherapy Products for Other Cancer Treatment, by Region, Through 2021
Table 31 : Global Market for Therapeutic Antibodies, by Region, Through 2021
Table 32 : Global Market for Checkpoint Inhibitors, by Region, Through 2021
Table 33 : Global Market for Interleukins, by Region, Through 2021
Table 34 : Global Market for Interferons, by Region, Through 2021
Table 35 : Global Market for Colony-Stimulating Factors, by Region, Through 2021
Table 36 : Global Market for Small Kinase Inhibitors, by Region, Through 2021
Table 37 : Global Market for Proteasome Inhibitors, by Region, Through 2021
Table 38 : Global Market for Immunomodulators, by Region, Through 2021
Table 39 : Global Market for Cancer Vaccines, by Region, Through 2021
Table 40 : Global Market for Lung Cancer Treatment, by Category, Through 2021
Table 41 : Global Market for Breast Cancer Treatment, by Category, Through 2021
Table 42 : Global Market for Leukemia Treatment, by Category, Through 2021
Table 43 : Global Market for Myeloma Treatment, by Category, Through 2021
Table 44 : Global Market for Colorectal Cancer Treatment, by Category, Through 2021
Table 45 : Global Market for Lymphoma Treatment, by Category, Through 2021
Table 46 : Global Market for Melanoma Treatment, by Category, Through 2021
Table 47 : Global Market for Kidney Cancer Treatment, by Category, Through 2021
Table 48 : Global Market for Bladder Cancer Treatment, by Category, Through 2021
Table 49 : Global Market for Head and Neck Cancer Treatment, by Category, Through 2021
Table 50 : Global Market for Stomach Cancer Treatment, by Category, Through 2021
Table 51 : Global Market for Treatment of Other Types of Cancer, by Category, Through 2021
Table 52 : Global Market for Oncolytic Virotherapy, Through 2021
Table 53 : Global Market for Oncolytic Virotherapy, by Region, Through 2021
Table 54 : Global Market for Oncolytic Virotherapy, by Indication, Through 2021

List of Figures

Figure 1 : Summary Figure: Global Market for Cancer Immunotherapy, by Region, 2015-2021
Figure 2 : Annual Incidence and Mortality Data for Lung Cancer in the U.S., 1975-2015
Figure 3 : Annual Incidence and Mortality Data for Lung Cancer in Five E.U. Countries, 1975-2012
Figure 4 : Annual Incidence and Mortality Data for Lung Cancer in Japan, 1975-2015
Figure 5 : Annual Incidence and Mortality Data for Lung Cancer in the Rest of the World, 1975-2012
Figure 6 : Five-Year Survival Rates, by Lung Cancer Stage
Figure 7 : Five-Year Survival Rates for Lung Cancer in the U.S., 1975-2008
Figure 8 : Annual Incidence and Mortality Data for Breast Cancer in the U.S., 1975-2015
Figure 9 : Annual Incidence and Mortality Data for Breast Cancer in Five E.U. Countries., 1975-2012
Figure 10 : Annual Incidence and Mortality Data for Breast Cancer in Japan, 1975-2012
Figure 11 : Annual Incidence and Mortality Data for Breast Cancer in the Rest of the World, 1975-2012
Figure 12 : Five-Year Survival Rates, by Breast Cancer Stage
Figure 13 : Annual Incidence and Mortality Data for Colorectal Cancer in the U.S., 1975-2015
Figure 14 : Annual Incidence and Mortality Data for Colorectal Cancer in Five E.U. Countries, 1975-2012
Figure 15 : Annual Incidence and Mortality Data for Colorectal Cancer in Japan, 1975-2015
Figure 16 : Annual Incidence and Mortality Data for Colorectal Cancer in the Rest of the World, 1975-2012
Figure 17 : Five-Year Survival Rates, by Colorectal Cancer Stage
Figure 18 : Annual Incidence and Mortality Data for Stomach Cancer in the U.S., 1975-2012
Figure 19 : Annual Incidence and Mortality Data for Stomach Cancer in Five E.U. Countries, 1975-2012
Figure 20 : Annual Incidence and Mortality Data for Stomach Cancer in Japan, 1975-2015
Figure 21 : Annual Incidence and Mortality Data for Stomach Cancer in the Rest of the World, 1975-2012
Figure 22 : Five-Year Survival Rates, by Stomach Cancer Stage
Figure 23 : Annual Incidence and Mortality Data for Head and Neck Cancer in the U.S., 1975-2015
Figure 24 : Annual Incidence and Mortality Data for Head and Neck Cancer in Five E.U. Countries, 1975-2012
Figure 25 : Annual Incidence and Mortality Data for Head and Neck Cancer in Japan, 1975-2015
Figure 26 : Annual Incidence and Mortality Data for Head and Neck Cancer in the Rest of the World, 1975-2012
Figure 27 : Five-Year Survival Rates, by Head and Neck Cancer Stage
Figure 28 : Annual Incidence and Mortality Data for Leukemia in the U.S., 1975-2015
Figure 29 : Annual Incidence and Mortality Data for Leukemia in Five E.U. Countries, 1975-2012
Figure 30 : Annual Incidence and Mortality Data for Leukemia in Japan, 1975-2015
Figure 31 : Annual Incidence and Mortality Data for Leukemia in the Rest of the World, 1975-2012
Figure 32 : Annual Incidence and Mortality Data for Cervical Cancer in the U.S., 1975-2015
Figure 33 : Annual Incidence and Mortality Data for Cervical Cancer in Five E.U. Countries, 1975-2012
Figure 34 : Annual Incidence and Mortality Data for Cervical Cancer in Japan, 1975-2015
Figure 35 : Annual Incidence and Mortality Data for Cervical Cancer in the Rest of the World, 1975-2012
Figure 36 : Five-Year Survival Rates, by Cervical Cancer Stage
Figure 37 : Annual Incidence and Mortality Data for Prostate Cancer in the U.S., 1975-2015
Figure 38 : Annual Incidence and Mortality Data for Prostate Cancer in Five E.U. Countries, 1975-2012
Figure 39 : Annual Incidence and Mortality Data for Prostate Cancer in Japan, 1975-2015
Figure 40 : Annual Incidence and Mortality Data for Prostate Cancer in the Rest of the World, 1975-2012
Figure 41 : Five-Year Survival Rates, by Prostate Cancer Stage
Figure 42 : Annual Incidence and Mortality Data for Melanoma in the U.S., 1975-2015
Figure 43 : Annual Incidence and Mortality Data for Melanoma in Five E.U. Countries, 1975-2012
Figure 44 : Annual Incidence and Mortality Data for Melanoma in Japan, 1975-2015
Figure 45 : Annual Incidence and Mortality Data for Melanoma in the Rest of the World, 1975-2012
Figure 46 : Five-Year Survival Rates, by Melanoma Stage
Figure 47 : Annual Incidence and Mortality Data for Ovarian Cancer in the U.S., 1975-2015
Figure 48 : Annual Incidence and Mortality Data for Ovarian Cancer in Five E.U. Countries, 1975-2012
Figure 49 : Annual Incidence and Mortality Data for Ovarian Cancer in Japan, 1975-2015
Figure 50 : Annual Incidence and Mortality Data for Ovarian Cancer in the Rest of the World, 1975-2012
Figure 51 : Five-Year Survival Rates, by Ovarian Cancer Stage
Figure 52 : Market Share of Leaders in Cancer Immunotherapy, 2016
Figure 53 : Global Market Share of Leaders in Oncolytic Virotherapy, 2021

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Abbvie Inc.
  • Avax Technologies
  • Daiichi Sankyo Co.
  • Immunomedics Inc.
  • Merck Serono
  • Sanofi SA
  • MORE

Analyst Credentials:

Ufuk Ezer. Ezer holds a bachelor's degree in bioengineering and a master's degree in biotechnology, bioprocessing and business management. He possesses extensive pharmaceutical research and development experience and has participated in projects for various international institutions and organizations. Ezer has been granted scholarships and awards during his post-study works in countries such as Japan and Panama based on the high quality of his work and excellence in the fields of research.

Note: Product cover images may vary from those shown
5 of 6
  • Abbvie Inc.
  • Adaptimmune
  • Aduro Biotech
  • Advantagene
  • Advaxis Immunotherapies
  • Amgen
  • Argos Therapeutics
  • Ariad Pharmaceuticals
  • Arog Pharmaceuticals
  • Aserta Pharmaceuticals
  • Astellas
  • Astrazeneca
  • Avax Technologies
  • Bavarian Nordic
  • Bayer Healthcare
  • Biovex
  • Boehringer Ingelheim
  • Boston Biomedical
  • Bristol-Myers Squibb
  • Cell Medica
  • Celldex Therapeutics
  • Celgene Corp.
  • Chugai
  • Cold Genesys
  • Daiichi Sankyo Co.
  • Dendreon
  • Dnatrix
  • Eisai
  • Eli Lilly
  • F Hoffmann La Roche AG
  • Genelux
  • Gilead Sciences Inc.
  • Glaxosmithkline Plc
  • Hanmi Pharmaceutical
  • Heat Biologics
  • Immune Design
  • Immunocellular Therapeutics Ltd.
  • Immunomedics Inc.
  • Immunovaccine Inc.
  • Immunovative Therapies
  • Incyte Ciorp.
  • Inovio Pharmaceuticals Inc.
  • Janssen Pharmaceuticals
  • Kadmon Pharmaceuticals Corp.
  • Kite Pharmaceuticals Inc.
  • Kyowa Hakko Kirin Co. Ltd.
  • Ligand Pharmaceuticals Inc.
  • Lion Biotechnologies
  • Lokon Pharmaceuticals AB
  • Medimmune
  • Merck & Co.
  • Merck Kgaa
  • Merck Serono
  • Medigene AG
  • Mirati Therapeutics
  • Multivir Inc.
  • Newlink Genetics
  • Northwest Biotherapeutics
  • Novartis Pharma Services AG
  • Oncolys Biopharma Inc.
  • Oncolytics Biotech Inc.
  • Oncomed Pharmaceuticals Inc.
  • Oncos Therapeutics Ltd.
  • Ono Pharmaceutical Co.
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Plexxikon Inc.
  • Portola Pharmaceuticals Inc.
  • Provectus Biopharmacueticals Inc.
  • Psioxus Therapeutics Ltd.
  • Sanofi SA
  • Seattle Genetics
  • Shanghai Sunway Biotech Co. Ltd.
  • Shenzhen Sibiono Gentech
  • Sillajen Biotherapeutics Inc.
  • Spectrum Pharmaceuticals
  • Takara Bio Inc.
  • Takeda Co. Ltd.
  • Tapimmune Inc.
  • Targovax
  • Teva Pharmaceutical Industries Ltd.
  • TG Therapeutics Inc.
  • Tracon Pharmaceuticals Inc.
  • Transgene
  • VCN Biosciences
  • Ventirx
  • Verastem Inc.
  • Viralytics Ltd.
  • Virttu Biologics Ltd
  • Vyriad
  • Western Oncolytics Ltd.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll